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Background: Thyroid peroxidase (TPO) is a dimeric membrane-bound enzyme of thyroid follicular cells, re-
sponsible for thyroid hormone biosynthesis. TPO is also a common target antigen in autoimmune thyroid
disease (AITD). With two active sites, TPO is an unusual enzyme, and thus there is much interest in under-
standing its structure and role in AITD. Homology modeling has shown TPO to be composed of different
structural modules, as well as a propeptide sequence. During the course of studies to obtain homogeneous
preparations of recombinant TPO for structural studies, we investigated the role of the large propeptide se-
quence in TPO.
Methods: An engineered recombinant human TPO preparation expressed in Chinese hamster ovary (CHO) cells
lacking the propeptide (TPODpro; amino acid residues 21–108) was characterized and its properties compared to
wild-type TPO. Plasma membrane localization was determined by cell surface protein biotinylation, and bio-
chemical studies were performed to evaluate enzymatic activity and the effect of deglycosylation. Im-
munological investigations using autoantibodies from AITD patients and other epitope-specific antibodies that
recognize conformational determinants on TPO were evaluated for binding to TPODpro by flow cytometry,
immunocytochemistry, and capture enzyme-linked immunosorbent assay. Molecular modeling and dynamics
simulation of TPODpro comprising a dimer of myeloperoxidase-like domains was performed in order to in-
vestigate the impact of propeptide removal and the role of glycosylation.
Results: The TPODpro was expressed on the cell surface at comparable levels to wild-type TPO. The TPODpro
was enzymatically active and recognized by patients’ autoantibodies and a panel of epitope-specific antibodies,
confirming structural integrity of the two major conformational determinants recognized by autoantibodies.
Faithful intracellular trafficking and N-glycosylation of TPODpro was also maintained. Molecular modeling and
dynamics simulations were consistent with these observations.
Conclusions: Our results point to a redundant role for the propeptide sequence in TPO. The successful expression of
TPODpro in a membrane-anchored, enzymatically active form that is insensitive to intramolecular proteolysis, and
importantly is recognized by patients’ autoantibodies, is a key advance for purification of substantial quantities of
homogeneous preparation of TPO for crystallization, structural, and immunological studies.
Introduction
Human thyroid peroxidase (TPO) is an oxidoreductasethat catalyzes thyroid hormone synthesis at the apical
membrane–colloid interface of thyrocytes by iodination of
tyrosyl residues of thyroglobulin, and subsequent coupling of
iodotyrosyl residues to form the thyroid hormones (1). TPO is
also a major antigenic target for autoantibodies in autoim-
mune thyroid disease (AITD) (2–4).
Polyclonal TPO antibodies present in the sera of patients
with AITD react with conformational epitopes restricted to
an immunodominant region (IDR) comprising chiefly of two
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overlapping regions A and B (2–4). These regions were firstly
defined in competition experiments with a panel of murine
monoclonal antibodies and patient autoantibodies (5), and
subsequent studies with recombinant human anti-TPO Fab
fragments confirmed these findings (6,7). Numerous attempts
have been made to identify the amino acids in the auto-
antibodies’ epitopes (8–18); however, to clearly interpret these
data and arbitrate between some conflicting results, the de-
termination of the three-dimensional structure of TPO in
complex with various autoantibodies is needed.
The human TPO gene on chromosome 2 is comprised of
150 kb, consisting of 17 exons and 16 introns (19). The protein
of 933 amino acids has been shown to have a large N-terminal
extracellular ectodomain, a single transmembrane region and
a short cytoplasmic C-terminal tail. The ectodomain is com-
posed of an N-terminal signal peptide, a propeptide, and
three domains: an N-terminal myeloperoxidase (MPO) do-
main (MPO-like, residues 142–738), a complement control
protein domain (CCP-like, residues 739–795), and a C-termi-
nal epidermal growth factor domain (EGF-like, residues 796–
841) (9). The signal peptide is encoded by part of exon 2, but
the exact physiological cleavage site remains unknown. It has
been proposed to occur between residues 14 and 15, 18 and 19,
or 26 and 27 (20). The propeptide is encoded by exons 2 to 4,
but its functions are unclear (20). Moreover, sequence align-
ment of TPO from different species indicates a high degree of
homology, except for the N- and C-terminal regions (21), but
interestingly the propeptide region of TPO in different species
shows minimal homology (20).
Newly synthesized TPO is transported from the endo-
plasmic reticulum to the cell surface via the Golgi complex
(20,22–24). During processing and intracellular trafficking
TPO interacts with the molecular chaperones calnexin, calre-
ticulin (25), and BiP (26). It also undergoes several post-
translational modifications, notably glycosylation, heme
fixation (within the MPO domain), proteolytic trimming, and
dimerization. On sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE), the purified TPO migrates as
two closely spaced bands of about 100 kDa and despite in-
tensive studies, it has been difficult to resolve whether the two
protein bands are derived by proteolytic processing, presence
of various mRNA species encoding for different TPO iso-
forms, or posttranslational modifications (20,27,28). Elegant
studies by Le Fourn and colleagues (20) on purified prepara-
tions of TPO from human thyroid tissue revealed N-terminal
processing to be at the end stage in the endoplasmic secretory
pathway. Furthermore, analysis of the effect of removal of the
postulated propeptide (Cys15–Lys108) on TPO expression in
Chinese hamster ovary (CHO) cells suggested that the pro-
peptide acts as an intramolecular chaperone facilitating
proper TPO folding (20). In our studies to obtain homoge-
neous preparations of the soluble TPO ectodomain for crys-
tallization and structural studies, we focused on enzyme
preparations lacking the propeptide sequence that are ex-
pressed in CHO cells. We obtained high levels of expression
and successfully purified a single species of recombinant TPO
lacking the TPO propeptide sequence. Surprisingly, our data
indicated that the absence of the propeptide sequence does
not appear to influence the folding, trafficking and cell sur-
face expression, incorporation of the heme moiety, enzy-




Recombinant human Fabs (rhFabs) specific for IDR-A
(126TP1 and 126TO10) and specific for IDR-B (126TP5 and
126TP14) were obtained and characterized as previously de-
scribed (6,29). Pooled sera from 20 patients with AITD were
obtained from the Regional Hospital Siedlce (Siedlce, Poland).
These sera were positive for TPO antibodies and were used as
a positive control in flow cytometry and capture enzyme-
linked immunosorbent assay (ELISA). A rabbit anti-peptide
P14 polyclonal antibody that specifically binds to region 599–
614 of TPO was generated and characterized previously
(9,10). Murine monoclonal antibody (mAb) A4 directed to a
linear epitope on TPO (30) was used in capture ELISA and
Western blotting. A murine mAb specific to beta-actin (clone
AC-15) from Abcam was used in Western blotting. We use the
terminology of IDR-A and -B established by Ruf et al. (5).
Construction of cDNA encoding wild-type TPO
and TPO lacking the propeptide and their expression
in Chinese hamster ovary cells
Cloning of full-length recombinant human TPO cDNA was
previously described (11). A cDNA coding for TPO lacking the
propeptide (TPODpro) was prepared using an overlap extension
polymerase chain reaction (PCR) (31). In the primary PCR am-
plifications, in which pcDNA5/FRT–wild-type TPO (TPOwt)
served as a template, the primers were upstream 5¢-CGC AAG
CTT GTC AGA ATG AGA GCG CTC GCT-3¢ plus downstream
5¢-TGG ATG CTG TGA TTG TTG AGT GAA GAA GGC TTC
TGT GCA GGC-3¢, and upstream 5¢-ACT CAA CAA TCA CAG
CAT CCA-3¢ and downstream 5¢-CAC GTA CTG CTG GAA
GGC CTC-3¢, respectively. The PCR products were isolated from
agarose gel and then simultaneously subjected to the secondary
PCR with the following primers: upstream 5¢-CGC AAG CTT
GTC AGA ATG AGA GCG CTC GCT-3¢ and downstream
5¢-CAC GTA CTG CTG GAA GGC CTC-3¢. The final product
was digested simultaneously with HindIII and BamHI and
cloned into pcDNA5/FRT vector (Life Technologies) resulting in
the construct pcDNA5/FRT/TPO HindIII-BamHI. Then the
BamHI-NotI fragment was subcloned from pcDNA5/FRT/
TPOe into pcDNA5/FRT/TPO HindIII-BamHI to generate
pcDNA5/FRT/DproTPOe. The construction of the pcDNA5/
FRT/TPOe vector, which contained the cDNA encoding the
extracellular domain of TPO, was conducted previously by
subcloning a NheI-NotI fragment from pCIneo/TPOe (10) to
pcDNA5FRT. Finally, a BamHI-NotI fragment was subcloned
from pcDNA5/FRT/TPOwt into pcDNA5/FRT/DproTPOe.
Transfection and expression of recombinant TPO in Chi-
nese hamster ovary (CHO) cells using the Flp-In expression
system was previously described (11). Cell lines resistant to
600 lg/mL Hygromycin B (Life Technologies) were propa-
gated for stable expression.
Total cell protein isolation and cell surface protein
biotinylation
Total cell proteins were extracted from CHO cells as pre-
viously described (12). Cell surface protein was isolated using
the Cell Surface Protein Isolation Kit (Pierce) according to the
protocol provided by the manufacturer. In brief, the cells were
grown to 90%–95% confluence and were then rinsed twice
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with ice-cold phosphate-buffered saline (PBS) and subse-
quently incubated for 30 minutes with 0.25 mg/mL Sulfo-
NHS-SS-Biotin in PBS at 4C. After quenching of the
remaining reactive Sulfo-NHS-SS-Biotin, the cells were lysed
in buffer supplemented with protease inhibitor cocktail
Complete (Roche). To isolate surface proteins, NeutrAvidin
Agarose beads were added and mixed for 1 hour at room
temperature. Biotinylated surface proteins were separated
from the intracellular protein fraction by centrifugation. The
beads were washed four times with the buffer provided by the
manufacturer supplemented with protease inhibitor cocktail
Complete (Roche), and the surface proteins were eluted by the
addition of SDS-PAGE sample buffer with 50 mM dithio-
threitol. The reaction was mixed for 1 hour at room temper-
ature. Actin was used as a control to show that the
intracellular proteins were not biotinylated.
Immunodetection of TPO
Proteins extracted from CHO cells were resolved by SDS-
PAGE gels under reducing and nonreducing conditions, and
electrophoretically transferred to nitrocellulose membranes.
The membranes were probed with anti-TPO mAb A4 and
anti-beta-actin mAb (Abcam) as primary antibodies, followed
by incubation with a horseradish peroxidase (HRP)-conju-
gated rabbit anti-mouse IgG (Dako), and developed using
chemiluminescence SuperSignal West Pico Substrate System
(Pierce). The amount of TPO expressed by CHO transfectants
was standardized by densitometry.
Immunocytochemistry
Cells grown on uncoated glass coverslips for 3 days were
washed with PBS, fixed with 4% paraformaldehyde for 15
minutes, followed by a brief wash in PBS and quenching with
50 mM NH4Cl in PBS for 10 minutes. The cells on selected
coverslips were permeabilized for 5 minutes with 0.1% Triton
X-100 in PBS. After three washes in PBS, all preparations were
then blocked with 2.5% goat serum and 2.5% bovine serum
albumin (BSA) in PBS for 1 hour. For the permeabilization, the
blocking and all subsequent incubation and washing steps
included 0.1% Tween 20. After brief washing in PBS, the cells
were incubated with mAb A4 (0.2 lg/mL) in blocking solu-
tion for 1 hour. The cells were washed three times with PBS
and incubated with goat anti-mouse IgG DyLight 549-conjugate
(Abcam) for 1 hour. The cells were further washed three times
with PBS and incubated with 4¢,6-diamino-2 phenylindole for
5 minutes. The cells were finally washed once in PBS before
mounting and visualization with a Zeiss AxioVision micro-
scope equipped with epifluorescence optics, digital camera,
and Zeiss AxioVision software. All steps were carried out at
room temperature.
Flow cytometry analysis
Cell surface expression of TPOwt and TPODpro was ana-
lyzed with anti-TPO-specific rhFabs and a pool of 20 sera from
patients with AITD positive for autoantibodies to TPO as
already described (8). A 48-hour culture of CHO cells was
detached from culture plates with nonenzymatic Cell Dis-
sociation Solution (Sigma-Aldrich) and washed with PBS
containing 0.1% BSA. The cells were resuspended and incu-
bated for 30 minutes at 4C with TPO-specific primary anti-
bodies, washed, and incubated for 30 minutes at 4C with
R-phycoerythrin-conjugated anti-human kappa (Caltag)
or fluorescein isothiocyanate–conjugated anti-human IgG
(Sigma-Aldrich). Then the cells were washed, fixed in 2%
formaldehyde in PBS, and evaluated (10,000 events) on a
FACSCalibur flow cytometer and analyzed with CellQuest
software (Becton Dickinson).
Capture ELISA
For assessing the binding of rhFabs, a pool of 20 sera from
patients with AITD and anti-P14 antibody to TPO was stud-
ied by capture ELISA as described with some minor modifi-
cations (8,11). In brief, the wells of polystyrene high-binding
microtiter plates (Costar) were coated with mAb A4 at
30lg/mL in carbonate-bicarbonate buffer containing 0.1%
sodium azide and incubated overnight at 4C. After each in-
cubation, wells were washed three times with TBS containing
0.1% Tween 20 (TBST). After blocking by incubation with TBS
containing 2 mg/mL BSA, total cell proteins extracted from
CHO cells were added at 10lg/mL in TBST containing 2 mg/
mL BSA (TBST-BSA). The following day, anti-TPO-specific
antibodies were diluted in TBST-BSA to give an OD at 450 nm
between 1.0 and 2.0, and incubated 1 hour at room tempera-
ture. The bound Fab fragments or patient or rabbit antibodies
were detected after incubation for 1 hour at room temperature
with a HRP-conjugated goat anti-human IgG Fab-specific
(Sigma-Aldrich), a HRP-conjugated rabbit anti-human IgG
(Sigma-Aldrich), or a HRP-conjugated goat anti-rabbit
IgG (Dako), respectively. The plates were developed with
0.1 mg/mL tetramethylbenzidine (TMB) in citrate buffer, pH
4.0. The reaction was terminated with 100lL of 1 M sulfuric
acid and optical density was measured at 450 nm in a mi-
crotiter reader (Multiscan RC, Labsystems).
Deglycosylation with Endo H and PNGase F
Protein samples were denatured by boiling for 10 minutes
in 0.5% SDS and 1% 2-mercaptoethanol. Samples were then
diluted with the buffer used for incubation with glycosidases.
Endo H (Roche) and PNGase F (New England Biolabs) di-
gestion were performed in 50 mM sodium acetate (pH 5.0) or
1% NP-40 in PBS (pH 7.5), respectively. The samples were
incubated for about 16 hours at 37C. Control reactions were
performed under the same assay conditions except that the
deglycosylation enzymes were omitted. Then the SDS-PAGE
sample buffer was added to each reaction.
Enzymatic activity of extracellular TPO
Enzymatic activity of TPO expressed at the surface of the
cell was determined as previously described (32) with some
minor modifications. CHO cells were grown for 48 hours in
six-well plates in a medium supplemented with 20lM hemin
(Sigma-Aldrich). The cells were washed two times with 2 mL
of PBS, then 0.5 mL of reaction mixture was added (100 lM KI
[Sigma-Aldrich], 200 U/mL SOD [Sigma-Aldrich], and 50 lM
Amplex Ultra Red [Life Technologies] in PBS). The reaction
was initiated by adding 25lL of 1 mM H2O2 (Sigma-Aldrich).
Twenty-microliter aliquots were removed at 1-minute inter-
vals during 8 minutes and immediately mixed with 80lL of
inhibition mixture containing 500 U/mL catalase (Sigma-
Aldrich) and 100 U/mL superoxide dismutase (Sigma-Aldrich)
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in PBS. The fluorescence was measured in a microtiter reader
(Synergy H4, Biotek) using excitation at 530 nm and emission
at 590 nm.
Statistical analysis
The statistical significance was determined by the Mann-
Whitney U test using Statistica 10.0 software (StatSoft, Inc.).
The difference was considered significant at p < 0.05.
Modeling the MPO-like domain dimer of TPO
A model of the human MPO-like domain from TPO (resi-
dues 139–736) was constructed first by querying the protein
sequence against the Protein Databank (PDB) using the NCBI
BLAST web server (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Searching through the resulting structures led to the selection
of bovine lactoperoxidase (LPO; PDB 3Q9K) as a template
structure, having a sequence identity of 47% with the MPO-
like domain from human TPO. This structure was selected
over the other high-identity structures because it features a
full contiguous structure, which is similar to the MPO-like
domain of TPO. The TPO-MPO sequence was aligned against
the 3Q9K sequence using ClustalW (33). Using the PDB
structure and sequence alignment, 100 homology models
were built using MODELLER (34). The best scoring model
was selected for building an MPO-like domain dimer using as
a template the structure of human MPO isoform C dimer
(PDB 1CXP). The interdimer disulfide bridge (residues 153 in
1CXP) was modeled in the MPO-like domain dimer model.
Molecular dynamics simulation of the MPO-MPO
domain dimer model of TPO
The MPO-MPO domain dimer model was placed into a
cubical box of 14.6 nm3 with a minimum distance of 1.4 nm
between the protein and the wall of the box. The system was
solvated in explicit water followed by the addition of counter-
ions (Na+ or Cl- ) to a concentration of 50 mM NaCl, thereby
neutralizing the net charge of the system. The simulation box
was subjected to a steepest descent energy-minimization before
commencing dynamics. To avoid unnecessary distortion of the
protein during the initial stages of simulation, a gradual posi-
tional restraints equilibration was used. Here, three consecu-
tive equilibration runs were performed in which all heavy
protein atoms were restrained to their starting positions using a
force constant of 1000, 100, and 10 kJ/mol/nm2 respectively.
The equilibration stage initially heated the system to 298 K
while restraining the heavy protein atoms with a force of
1000 kJ/mol/nm2 for 100 picoseconds. The restraining force
was released to 100 kJ/mol/nm2 for 100 picoseconds, followed
by the release to 10 kJ/mol/nm2 for another 100 picoseconds.
The equilibrated MPO-MPO domain dimer system was then
subjected to a production simulation for 300 nanoseconds, with
configurations stored every 10 picoseconds for analysis. Si-
mulations were carried out using GROMACS Ver. 4.0.7 (35) in
conjunction with the GROMOS 53A6 united-atom force field
(36). Ionizable residues were in their standard protonation
states at pH 7.0. Water was explicitly represented using the
simple-point-charge model (37). Simulations were performed
in an NPT ensemble under periodic boundary conditions. Si-
mulation conditions were roughly the same as described in
Oostenbrink et al. (36). The temperature was maintained close
to its reference value of 298 K by independent weak-coupling of
the protein and solvent to an external temperature bath with a
coupling constant of sT= 0.1 picoseconds (38).
The pressure was maintained close to its reference value of
1 bar by isotropic weak-coupling of the atomic coordinates
and box dimensions to a pressure bath (38), using an iso-
thermal compressibility value of 4.6 · 10 - 5/bar and a cou-
pling constant of sP = 1 picosecond. During the simulations,
the bond length within the protein was constrained using the
P-LINCS algorithm (39) and water geometry was constrained
using the SETTLE algorithm (40). The time step used for in-
tegrating the equations of motion was 2 femtoseconds.
Nonbonded interactions were evaluated using a twin-
range cutoff scheme: interactions falling within the 0.8 nm
FIG. 1. Western blot analysis of TPOwt and TPODpro expressed in CHO cells under (A, B) reducing and (C) nonreducing
conditions. Five micrograms of total cell lysate was loaded onto 8% SDS-PAGE per lane, transferred to nitrocellulose
membranes and probed with (A, C) anti-TPO mAb A4 and (B) anti-beta-actin mAb. One representative immunoblot from
independent experiments (n ‡ 3) is shown. The densitometric quantification (means – SD) of the bands is shown on the top of
panels (A) and (B). Non-transfected CHO cells were used as a negative control (A, B). TPO, thyroid peroxidase; wt, wild-
type; TPODpro, recombinant human TPO preparation lacking the propeptide; CHO, Chinese hamster ovary; SDS-PAGE,
sodium dodecyl sulfate polyacrylamide gel electrophoresis; mAb, monoclonal antibody.
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short-range cutoff were calculated every 2 femtoseconds,
whereas interactions within the 1.4-nm-long cutoff were up-
dated together with the pair list every 10 femtoseconds. A
reaction-field correction was applied to the electrostatic in-
teractions beyond the long-range cutoff (41) using a relative
dielectric permittivity constant of eRF = 62 as appropriate for
simple-point-charge water (42). The system was simulated
three times independently, each time starting with a different
distribution of initial velocities.
Results
Construction, expression, and immunoreactivity
of TPOwt and TPODpro
We constructed a TPO-cDNA, called TPODpro lacking the
sequence encoding Pro21–Lys108, but with an intact signal
sequence (residues 1–20) for expression in CHO cells. Full-
length TPOwt produced in CHO cells was used as a control.
Immunoblotting analysis under reducing conditions of total
cell lysates revealed that TPODpro is expressed at a similar
level as TPOwt (Figs. 1A and 1B). Under nonreducing con-
ditions, we observed the presence of high molecular weight
TPO bands in total cell lysates extracted from both TPOwt and
TPODpro (Fig. 1C).
We then examined the immunofluorescence localization
of TPOwt and TPODpro in nonpermeabilized (Fig. 2A)
and permeabilized CHO cells (Fig. 2B). Thyroid peroxidase
was detected with linear epitope-specific antibody mAb
A4. Both TPOwt- and TPODpro-expressing cell lines, after
treatment with Triton X-100, showed strong perinuclear and
reticular fluorescence throughout the cytoplasm, suggest-
ing localization in the endoplasmic reticulum. Under
FIG. 2. Immunofluorescence distribution of thyroid peroxidase in stably transfected CHO cells expressing TPOwt (ii) and
TPODpro (iii). Non-transfected CHO cells were used as a negative control (i). Fixed cells were nonpermeabilized (A) or
permeabilized with 0.1% Triton X-100 (B). TPO was detected using mAb A4 and visualized with goat anti-mouse IgG
DyLight 549 (red) conjugate at · 100 magnification. 4¢,6-Diamino-2 phenylindole (blue) was applied to visualize nuclei. One
representative of three experiments is shown. Color images available online at www.liebertpub.com/thy
FIG. 3. Flow cytometry analysis
of binding of recombinant hu-
man Fabs (rhFabs) 126TO10 and
126TP14 (specific for IDR-A and -B,
respectively) and a pool of 20 sera
from patients with autoimmune
thyroid disease (AITD) to TPOwt
and TPODpro expressed on the
surface of stably transfected CHO
cells. Non-transfected CHO cells
were used as a negative control.
Fluorescence was developed as de-
scribed in Materials and Methods.
Data are representative of two in-
dependent experiments. Mean val-
ues of fluorescence are shown in
boxes.
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nonpermeabilization conditions, the same lines exhibited
immunofluorescence that was located at the cell membrane
with a punctuate pattern. TPO-specific staining was not
observed in a non-transfected CHO cell line used as a neg-
ative control (Fig. 2A-i, B-i). These results suggest that
the cell distribution of full-length and truncated TPO is
comparable.
Flow cytometry and anti-TPO Ab reactivity were used to
confirm the cell surface exposure of truncated and wild-type
TPO (Fig. 3), as indicated by immunofluorescence. First, we
verified that cell lines express TPO at the surface using a
human anti-TPO serum pool. We observed a similar positive
binding profile between the TPODpro and TPOwt cell lines,
whereas no binding was observed with the control cells (non-
transfected CHO cells). Next, we evaluated the reaction of
wild-type and truncated TPO with IDR-A (126TO10)-specific
and IDR-B (126TP14)-specific rhFabs (Fig. 3). These results
demonstrate that the reactivity of truncated TPO with con-
formation-dependent antibodies is not substantially affected
by removal of the propeptide.
To confirm that the TPODpro was immunologically intact
we applied capture ELISA tests with mAb A4 (Fig. 4). We
showed earlier (8) that this method is more sensitive than flow
cytometry in detecting changes in the antibody–antigen re-
activity. In this study, we used four rhFabs, two specific for
region A (126TO10 and 126TP1) and two specific for region B
(126TP5 and 126TP14), polyclonal anti-peptide P14 rabbit
serum, interacting with region B (9,10), and a pool of sera
collected from patients with AITD. We observed small but
statistically significant reductions in the reactivity of trun-
cated TPO with all tested antibodies except for rabbit anti-
peptide P14 serum (Fig. 4). In all cases, the decrease in the
reactivity was never greater that about 20%.
Extracellular TPO activity
To analyze extracellular TPO activity, we incubated CHO
cells expressing truncated and wild-type TPO (positive con-
trol) and non-transfected CHO cells (negative control) with
sensitive fluorogenic substrate (Amplex Ultra Red, Life
Technologies) in the presence of hydrogen peroxide. Accu-
mulation of the fluorescent reaction product was measured in
real time. Each well was seeded with the same number of cells
to reach 100% confluence on the day of experiment. Cells were
grown in the culture medium supplemented with heme pre-
cursor (hemin).
We observed similar TPO activity in both TPO-expressing
cell lines (Fig. 5), confirming that truncated TPO is effectively
transported to the cell surface and acquires full enzymatic
activity. To confirm the validity of the method, we conducted
additional control experiments, in which CHO cells expres-
sing TPOwt secreted into the culture medium (TPO ectodo-
main) and thyrotropin receptor (protein bound to the cell
membrane) were used (data not shown). Neither control cell
lines resulted in peroxidase activity as measured by the oxi-
dation of fluorogenic substrate (activity level similar to that of
non-transfected CHO cells).
Analysis of glycosylation
While determining the TPO expression in total cell lysates
extracted from CHO cells by immunoblotting (Fig. 1A), we
observed, surprisingly, that truncated TPO migrated under
FIG. 4. Relative reactivity of rhFabs specific for IDR-A (126
TP1 and 126TO10) and IDR-B epitopes (126TP5 and
126TP14), rabbit anti-peptide P14 serum (specific for IDR-B),
and a pool of 20 sera from patients with AITD to TPOwt and
TPODpro by capture enzyme-linked immunosorbent assay
(ELISA). Total cell lysates from CHO cells were captured
onto microtiter plates coated with anti-TPO mAb A4, fol-
lowed by incubation with the appropriate anti-TPO anti-
bodies. Data are presented as percentage values of TPOwt
reactivity (means – SD). Background binding to membrane
proteins prepared from non-transfected CHO cells was
subtracted from the antibody binding to proteins extracted
from CHO cells expressing TPOwt and TPODpro. The results
shown are representative of three independent experiments,
performed in triplicate wells. The OD values (means – SD)
for TPOwt and TPODpro, respectively, from one represen-
tative experiment with rhFab 126TO10 are 1.99 – 0.08 and
1.83 – 0.02; with rhFab 126TP1, 1.99 – 0.10 and 1.77 – 0.04;
with rhFab 126TP5, 1.82 – 0.06 and 1.72 – 0.04; with rhFab
126TP14, 1.95 – 0.06 and 1.86 – 0.02; with rabbit anti-P14 se-
rum, 1.53 – 0.12 and 1.50 – 0.01; and with patients’ pool,
1.35 – 0.12 and 1.32 – 0.01. Asterisks mark statistically sig-
nificant differences in antibody binding between TPOwt and
TPODpro determined using the Mann-Whitney U test
(*p < 0.05).
FIG. 5. Extracellular activity of TPO measured by the
Amplex Ultra Red (Life Technologies) oxidation of cells ex-
pressing TPOwt and TPODpro. Non-transfected CHO cells
were used as a negative control. Data are presented as rel-
ative fluorescence units (means – SD).
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reducing conditions as a double band (104.2 – 7.3 and
98.0 – 3.0 kDa), in contrast to a single band observed for
TPOwt (107.6 – 2.6 kDa). We hypothesized that two bands of
TPODpro may originate from differential N-linked glycosyl-
ation. Thus, we incubated total cell lysates with PNGase F in
an attempt to remove all asparagine-linked sugar moieties
(Fig. 6). After treatment with PNGase F, TPODpro migrated
on SDS-PAGE gel as a single distinct band (83.4 – 3.1 kDa)
(Fig. 6, lane 4). This strongly suggests that truncated TPO
undergoes posttranslational N-glycosylation, acquiring ap-
proximately 17 kDa of N-linked carbohydrate. This is consis-
tent with the reported 12 kDa N-linked glycosylation of
TPOwt (20). PNGase F-treated TPOwt yielded three bands
(99.1 – 3.6, 94.9 – 0.1, 92.6 – 5.2 kDa; Fig. 6, lane 2), again con-
sistent with the results reported by Le Fourn et al. (20).
To characterize the N-glycosylation process more precisely
and to confirm immunofluorescence and flow cytometry re-
sults showing that TPODpro is transported to the cell surface,
we isolated the intracellular and surface fraction of CHO cell
proteins by the cell surface biotinylation technique. In this
method, a membrane-impermeable reagent labeled with a
biotin moiety forms a stable covalent linkage with amino
groups of lysine residues that are exposed on the cell surface
and are freely accessible to solvent. Subsequently, the intra-
cellular and surface fractions were subjected to deglycosyla-
tion with Endo H or PNGase F (Fig. 7). Whereas PNGase F
removes all N-linked oligosaccharides (high mannose- and
complex-type structures), Endo H digests only mannose-type
residues. Newly synthesized polypeptides first acquire high
mannose carbohydrates, which are then modified (trimmed
and remodeled) by a variety of transferases and glycosidases
to complex oligosaccharides during passage through the
Golgi apparatus. Therefore, we reasoned that using Endo H
digestion to measure the amount of mannose and/or complex
oligosaccharide attached to TPO would indicate if protein
secretion occurs via the Golgi complex (43).
We detected TPO-specific bands in the intracellular and
surface protein fractions, indicating that truncated TPO is
transported to the cell membrane (Fig. 7, lanes 1 and 4), con-
sistent with the data obtained by immunofluorescence and
flow cytometry (Figs. 2 and 3). Surprisingly, the surface-
presented TPODpro appeared as a distinct single band (Fig. 7,
lane 1), while intracellular TPODpro migrated on the SDS-
PAGE gel as a double band (Fig. 7, lane 4). After PNGase F
digestion, the intracellular and surface fractions of TPODpro
yielded a single band (Fig. 7, lanes 3 and 6). Endo H treatment
of the intracellular fraction resulted in partial digestion of
TPODpro (Fig. 7, lane 5), whereas the surface fraction was
Endo H resistant (Fig. 7, lane 2). In conclusion, it appears that
propeptide-deprived TPO, similarly to TPOwt, is transported
to the cell surface by the secretory pathway mediated by
the Golgi complex. The TPODpro propeptide bears high-
mannose oligosaccharides that are transformed into a complex-
type structure; therefore, all the TPODpro molecules detected at
the cell surface are Endo H resistant. For comparison, part of
the TPOwt molecules detected at the cell surface is still Endo H
sensitive (20,22). These differences between TPODpro and
TPOwt maturation will be discussed later.
Molecular modeling and sequence analysis
of TPODpro
The crystal structure of a mammalian thyroid peroxidase
has not yet been determined. However, human TPO shares
considerable sequence similarity with related human peroxi-
dases of known three-dimensional structure (Supplementary
Fig. S1; Supplementary Data are available online at www
.liebertpub.com/thy). Alignment with the human sequences
of eosinophil peroxidase, LPO, and MPO shows high simi-
larity within the MPO-like domain, as well as the predicted
signal peptide. However, while all sequences contain an N-
terminal propeptide, there is virtually no detectable similarity
in this region (Supplementary Fig. S1). It is interesting that
TPO is unique in the animal heme-dependent peroxidase
family in that it also contains two C-terminal domains, the
CCP-like and the EGF-like domain (Supplementary Fig. S1).
The high sequence similarity of TPO with MPO-like do-
mains with known crystal structures allowed us to build a
homology model for the MPO-MPO domain dimer of TPOD
pro (Fig. 8). There are several reports of modeling, including
from the authors (8,9) and from other laboratories (12–14). We
FIG. 6. Deglycosylation of TPOwt and TPODpro expressed
in CHO cells. After digestion with PNGase F, total cell ly-
sates were subjected to 8% SDS-PAGE, followed by Western
blotting, and probing with anti-TPO mAb A4. Controls were
done under the same conditions as the corresponding assay,
except that enzyme was omitted. One representative im-
munoblot from independent experiments (n ‡ 3) is shown.
FIG. 7. Deglycosylation of TPODpro expressed in CHO
cells present at the cell surface or in the intramolecular
compartments with Endo H and PNGase F. After cell surface
biotinylation and extraction, isolated proteins were digested
with appropriate deglycosylation enzyme. Controls were
done under the same conditions as the corresponding assay,
except that enzymes were omitted. Samples were then sub-
jected to SDS-PAGE, followed by Western blotting, and
probing with anti-TPO mAb A4. One representative immu-
noblot from independent experiments (n ‡ 3) is shown.
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have exploited more recent high-resolution protein structures
of homologues of the peroxidase family members and up-to-
date molecular simulation methods in order to explore in
more detail the structural and dynamic properties of the TPO
dimer, and specifically the potential impact of propeptide
removal and location of glycosylation sites. Our model has
several important features. All three of the predicted aspara-
gine-linked glycosylation sites (predicted using the NetNGlyc
server; http://www.cbs.dtu.dk/services/NetNGlyc) map to
the MPO-like domain, with one of them located at the dimer
interface, mapping almost exactly to the location of the bound
sugar moiety observed in the crystal structure of human MPO
(incorporated in the TPO model; Fig. 8A). It is likely that the
N-linked carbohydrate chain, consisting of (GlcNac)2-(Man)3
structure with a fucose 1–6 linked to the first GlcNac, makes
stabilizing interactions with each MPO-like domain of TPO at
the dimer interface in an analogous fashion to human MPO.
Monomers are covalently linked by a disulfide bond that is
conserved in members of the human peroxidases that adopt
the MPO-like fold (Fig. 8), despite TPO, along with human
MPO being the only members of the animal peroxidase family
to exist as a functional dimer.
The structure of the N-terminal propeptide cannot be
modeled with any confidence; except for the signal peptide
region, it shares almost no sequence similarity with other
human peroxidases (Supplementary Fig. S1). Interestingly,
the propeptides of TPO, MPO, eosinophil peroxidase, and
LPO are almost exactly the same length, with very few in-
sertions or deletions. Despite the low similarity, there are
nevertheless a few conserved residues, suggesting a very
distant common ancestor; the extreme divergence in sequence
is consistent with the lack of a structure-dependent functional
role, which accords with our findings. Furthermore, the sim-
ilar lengths of the propeptides also argue against a role in any
interaction with the CCP- or EGF-like domains, since these
domains are present uniquely in TPO. The TPO propeptide is
moderately conserved among mammalian TPO enzymes
(Supplementary Fig. S2), suggesting a rather limited role in
folding and activity, also consistent with our findings. Our
model predicts that the propeptide is most likely solvent ex-
posed (Fig. 8); however, its likely location and mode of in-
teraction with the dimer, if any, cannot be predicted with any
confidence. Although it shares no sequence similarity with
any known structure, it is not predicted to be disordered ac-
cording to DisEMBL (44) and is predicted to be mainly helical
according to PsiPred (45). The molecular surface of our
TPODpro dimer model in the vicinity of where the propeptide
would most likely reside is irregular, deeply pitted, and hy-
drophilic, with clusters of positively charged regions and
smaller negatively charged patches (Fig. 8C). Given that the
propeptide sequence is predicted to be positively charged at
neutral pH (predicted pI = 10.2, containing 16 positively
charged and 9 negatively charged residues), its interaction
with the positively charged surface near the TPO-TPO dimer
interface is probably relatively weak. This is again consistent
with our findings.
Simulation of the model for 300 nanoseconds revealed
overall moderate flexibility, although the dimer interface and
the N-terminal regions were less flexible (Supplementary Video
S1). The conserved disulfide bonds at the dimer interface and
the intradomain bridge immediately after the propeptide are
likely explanations for the observed rigidity in these regions.
The flexibility elsewhere may be important in any structural
rearrangements necessary to accommodate a propeptide.
Discussion
Newly synthesized TPO undergoes a number of post-
translational modifications that result in a glycosylated, en-
zymatically active dimer located at the apical membrane of
human thyrocytes. Moreover, during maturation, the pro-
peptide region is proteolytically removed. In the present work
for ongoing crystallization studies, we focused on the role of
the propeptide TPO in expression, posttranslational modifi-
cations, and intracellular trafficking in CHO cells.
FIG. 8. Model of the myeloperoxidase (MPO)-like domain
dimer of TPO. (A, B) Orthogonal views showing the dimer
represented as cartoon with monomers colored differently.
Heme groups buried in the core of each monomer are shown
as space-filling atoms. Putative glycosylation sites are indi-
cated by blue sticks and labeled, and the N-linked carbohy-
drate chains are also shown in space filling representation,
making contact with each other at the edge of the dimer
interface. The interdimer disulfide bridge is indicated in
magenta. (C) Electrostatic potential surface of the TPO dimer
model in same orientation as (A). N- and C-termini are la-
beled; negative = red; positive = blue. Color images available
online at www.liebertpub.com/thy
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We report that propeptide-deleted TPO (TPODpro, lacking
Pro21–Lys108) is expressed in CHO cells at a comparable level
to TPOwt (depending on the method used for TPO expression
determination). Importantly, TPODpro is transported to the
cell surface and effectively recognized by antibodies with
binding specificity for the two key TPO conformational de-
terminants, IDR-A and IDR-B. Fayadat et al. (46) showed that
correct TPO protein folding is a critical event in its biosyn-
thesis and secretion. Only properly folded molecules are de-
livered to the cell membrane, while unfolded or partially
unfolded/misfolded proteins are degraded by the protea-
some or other proteases, respectively (46). More recently it
was shown that nonproteosomal TPO degradation is medi-
ated by plasminogen-like protease (47). Therefore, our find-
ings that TPODpro is effectively transported to the cell surface
where it reacts with conformation-dependent antibodies
suggests that the presence of the propeptide is not necessary
for proper folding of TPO. These findings contrast the results
of Le Fourn et al. (20). Using metabolic labeling and cell sur-
face protein biotinylation, they reported total inhibition of
TPO transport to the cell membrane in CHO cells stably
transfected with TPODpro cDNA.
Other studies of the role of the N-terminal propeptide in the
folding of mammalian peroxidases are not unambiguously
consistent with our findings. The best characterized member
of this family is human MPO. Wild-type MPO is targeted for
storage in granules by a regulated pathway, or secreted out-
side the cell by a constitutive pathway (43). Detailed studies
on the role of the propeptide in maturation and sorting of
MPO in myeloid 32D cell line revealed that MPODpro was
effectively transported to the culture medium by the secretory
pathway, but the intracellular trafficking to the storage
granules was completely blocked (48). Therefore, the pro-
peptide is likely to have an important role in the proper cel-
lular sorting of MPO. In comparison, TPO targeting is less
complicated since the protein only needs to be targeted to the
cell surface. It has been shown that an MPO-TPO chimera, in
which the amino terminus (residues 1–166) of full-length TPO
was replaced with the homologous MPO propeptide (resi-
dues 1–121), was delivered to the cell surface of CHO cell, as
determined by flow cytometry (18). This implies that the
propeptide may not be required for the transportation of TPO
and MPO to the cell membrane and outside the cell, respec-
tively.
However, in a more recent article, it was shown that
MPODpro is probably misfolded (49). An MPO mutant lack-
ing the propeptide, stably expressed in K562 cells (a human
hematopoietic cell line), failed to exit from the endoplasmic
reticulum (49). In addition to MPO-TPO chimera proteins
mentioned above, the fate of other fusion proteins tagged with
the MPO propeptide and subsequently expressed in myeloid
and nonmyeloid cell lines have been studied (49,50). In non-
myeloid cell lines (CHO cells and BHK cells), the propeptide
directs lysozyme partly to an intracellular compartment and
partly to the culture medium (50); however, in myeloid cell
lines (32D, K562, and PLB-985), the presence of the propeptide
was not sufficient to direct reporter proteins (soluble tumor
necrosis factor-a receptor, green fluorescein protein, and a1-
microglobulin) to the correct intracellular destination as in the
case of wild-type MPO (49). It is possible that the propeptide
alone is not sufficient to direct MPO to its proper intracellular
destination in myeloid cells that normally process endoge-
nously expressed MPO. It may be assumed that the propep-
tide of MPO interact via intramolecular interactions that are
not reconstructed in the fusion proteins (49,50). Also, whereas
TPO and MPO are dimers, other peroxidases are active in the
monomeric form, and thus the interactions with the propep-
tide are likely to be different. The role of propeptide in the
monomeric LPO in maturation and trafficking is poorly un-
derstood. It has been reported that LPODpro expressed in
baculovirus-insect cells is secreted to the culture medium (as
in wild-type LPO) in an enzymatically active form (51).
A possible explanation for the proper folding and sorting of
TPODpro in comparison with MPODpro and LPODpro may
lie in the unique domain architecture of TPO. In contrast to all
other peroxidases, TPO contains C-terminal CCP-like and
EGF-like domains, in addition to a membrane-anchoring
segment. It is possible that these domains, which adopt
compact, stable structures, interact favorably with the MPO-
like domain of TPO, effectively stabilizing the TPO dimer
such that its reliance on a propeptide for correct folding and
assembly is lessened. Furthermore, subsequent anchoring to
the membrane would be expected to add further stability to
the folded dimer.
In the present study, we also focused on the impact of
propeptide deletion on the asparagine-glycosylation process.
Asparagine-linked glycosylation is known to favorably en-
hance the folding and sorting of nascent protein in several
ways. Attached oligosaccharide moieties are recognized by
lectin-like molecular chaperones such as calnexin and calre-
ticulin, promoting correct protein folding. Furthermore, N-
glycans stabilize the structure of proteins and play a role in
their quality control and adequate sorting (52,53). Here we
provide evidence that TPODpro is N-glycosylated and pos-
sesses high-mannose N-linked oligosaccharides that are sub-
sequently completely processed into complex carbohydrate
side chain moieties. MPODpro secreted to the culture medium
also contains only complex-type N-linked moieties (48). This
observation may support our conclusion that TPODpro,
similarly to previously reported MPODpro (48), is transported
from the endoplasmic reticulum to the cell surface through the
secretory pathway. During transit, TPODpro and MPODpro
are transferred to the Golgi apparatus where they acquire
complex oligosaccharides. However, we cannot exclude that
the N-glycosylation process of membrane-anchored TPODpro
and secreted MPODpro is different to some extent. This is
consistent with the observation that the subcellular fraction of
MPODpro is susceptible to Endo H (48), while TPODpro de-
tected inside the cell is only partly Endo H resistant. It is
tempting to speculate that this discrepancy may be assigned
to the different cell lines used for expression of truncated TPO
(CHO cell line) and truncated MPO (32D cell line).
Our results revealed that TPODpro is enzymatically active
and forms dimers. It has already been demonstrated that the
attachment of heme residues to the TPO molecule is essential
for delivery of TPO to the cell surface (54). The MPO molecule,
as well as all other members of the mammalian peroxidase
family, contains heme as a prosthetic group (43). Heme is
incorporated into MPO before its exit from the endoplasmic
reticulum and is required for proper folding (55). Interest-
ingly, human MPODpro is enzymatically active (with some
minor reduction in efficiency of heme incorporation in com-
parison with wild-type MPO) when expressed in 32D cells
(48); however, the same construct expressed in K562 cells
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lacked heme (49). Importantly, human LPODpro demon-
strated similar enzyme activity compared with the activity of
recombinant wild-type LPO and bovine LPO (51). Also, in-
hibition of propeptide cleavage in TPOwt expressed in CHO
cells increased its enzymatic activity protein, implying that
enzyme activity is not hindered by the presence of the pro-
peptide (20). Taken together, the evidence suggests that the
propeptide has no observable impact on enzymatic activity of
TPO (neither negative nor positive), and this may also apply
to other mammalian peroxidases, at least for MPO and LPO.
In this study we have shown for the first time that TPODpro
forms enzymatically active dimers, supporting our hypothe-
sis that truncated TPO matures properly in CHO cells. In
addition to TPO, MPO is the only other mammalian peroxi-
dase that forms dimers that are necessary for targeting to the
granules—all other secreted members of the family exist as
monomers (43).
It has been suggested that the propeptide of TPO functions
as an intramolecular chaperone (20). Such intramolecular
chaperones are generally encoded as an N-terminal or a
C-terminal extension and do not contribute to the protein
function, but they are critical for proper folding. The in-
tramolecular chaperones are removed from the proteins when
the folding process is completed (56). It is often observed that
the intramolecular chaperone and the associated protein need
not be covalently linked for correct chaperone function (57).
Co-expression in trans of TPO propeptide and TPODpro in
CHO cells did not restore the proper folding of truncated TPO
(20). A similar conclusion was drawn by Bu¨low et al. (49) with
reference to MPO.
It remains unclear why our results presented here contrast
with observations indicating an important role of the pro-
peptide in TPO folding and sorting (20). There are several
differences between this and the previous study that may
contribute to the discrepancies. Our TPODpro construct con-
tained a 20-residue signal peptide compared to 14 residues in
the study by Le Fourn et al. (20). Importantly, Le Fourn et al.
(20) also examined the effect of using a slightly longer leader
sequence (residues 1–26); however, they did not observe any
improvement in TPODpro expression and maturation. Ad-
ditionally, in contrast to the mouse anti-TPO antibody that
binds to both partially and completely folded TPO used by Le
Fourn et al. (20), we used a different and wider panel of human
anti-TPO mAbs that have been shown to be specific to con-
formational epitopes on properly folded TPO (6,8,11).
In summary, we present for the first time an in-depth in-
vestigation into the role of the propeptide in the folding,
sorting, and function of recombinant human TPO. We pro-
vide novel data suggesting that truncated TPO is effectively
expressed, transported, and matured in CHO cells. In addi-
tion we have performed modeling that allows us to rationalize
the role of glycosylation and the propeptide on a structural
basis. Therefore, we suggest that it is highly likely that the
propeptide of TPO does not function as an intramolecular
chaperone. Nevertheless, it is unlikely that a propeptide that
constitutes approximately 10% of the whole TPO molecule
does not play some role in TPO structure and function. It
cannot be excluded that the full-length protein possesses ad-
ditional, important properties compared to the truncated
version. For example, the propeptide may play a role in ac-
celerating folding, as observed for subtilisin (58), or making
key interactions during the folding pathway that reduce the
accumulation of off-pathway folding intermediates and
aggregates.
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